1. Introduction {#sec1}
===============

Bromodomains are conserved acetyl-lysine-specific protein-interaction modules ([@bib13]). Bromodomain-containing proteins (BDPs) have been shown to play important roles in regulating eukaryotic gene expression and mutations or changes in the expression of BDPs has been linked to human diseases, including cancer, inflammation, neurological disorders, cardiovascular disease and diabetes ([@bib12]; [@bib20]). As a result of these links, BDP inhibitors are under investigation as drug leads, with the hope that interfering with lysine acetylation mediated signalling may be therapeutic ([@bib23]).

Similar to higher eukaryotes, the epigenetic regulation of gene expression is important in human protozoan pathogens. For example, parasites such as *Toxoplasma*, *Trypanosoma* and *Plasmodium* that cause toxoplasmosis, typanosomiasis and malaria, respectively, rely on epigenetic modifications to regulate gene expression ([@bib17])*.* BDPs have also been identified in all of these parasites, and have been hypothesized to be potential drug targets (reviewed in ([@bib17])). Seven BDP encoding genes have been annotated in *Plasmodium falciparum* ([@bib17]), with two partially characterised to date. *P. falciparum* histone acetyltransferase GCN5 (*Pf*GCN5; PF3D7_0823300) has been shown to have lysine acetyltransferase (KAT) activity ([@bib10]; [@bib18]) and *P. falciparum* bromodomain protein 1 (*Pf*BDP1; PF3D7_1033700) has been shown to be involved in the regulation of invasion-related genes in asexual stage parasites ([@bib19]). Both of these BDPs appear to be essential for parasite growth ([@bib19]; [@bib7]). While the crystal structure of *Pf*GCN5 bromodomain in complex with a triazolophthalazine-based small molecule inhibitor (L-45/L-Moses) has been reported ([@bib21]), there is a gap in our knowledge with respect to studies investigating the growth inhibitory effect of BDP binders/inhibitors against malaria parasites (reviewed in ([@bib17])). In this study, a panel of 42 potential BDP binders/inhibitors, including 38 identified by an *in silico* pharmacophore screen, were examined for predicted binding to *P. falciparum* BDP/bromodomains and for *in vitro* growth inhibitory activity against asexual-stage *P. falciparum* infected erythrocytes. The three most potent anti-plasmodial compounds were assessed in an additional *P. falciparum* growth inhibition assay, and for cytotoxicity against a mammalian cell line.

2. Methods {#sec2}
==========

2.1. Compounds {#sec2.1}
--------------

The anti-plasmodial control drug chloroquine diphosphate salt (Sigma-Aldrich, USA) was prepared as a 10--20 mM stock in phosphate buffered saline (PBS). The BDP binders/inhibitors bromosporine, CPI-203, PFI-4 and SGC-CBP30 (all from Selleck Chemicals, USA) were prepared as 10--20 mM stocks in DMSO. A further 38 compounds ([Table 1](#tbl1){ref-type="table"}) were obtained from the Princeton Biomolecular Research, Inc. (Princeton, NJ, USA) compound library, and prepared as 10--20 mM stocks in DMSO. These 38 compounds were selected based on virtual screening of a pharmacophore model of the bromodomain of PF3D7_0110500 (PDB ID [4PY6](pdb:4PY6){#intref0010}), selected as it was the only *P. falciparum* bromodomain/BDP in the Protein Databank ([@bib4]) crystallized in complex with an inhibitor (the PLK1 kinase/BRD4 dual inhibitor BI-2536) ([@bib5]). Based on the crystal structure of PF3D7_0110500 (PDB ID [4PY6](pdb:4PY6){#intref0015}) in complex with BI-2536, a pharmacophore model was generated using the program LigandScout 3.1 ([@bib27]). Residues of the protein binding pocket were assigned as excluded volume features. The model was manually curated: the hydrophobic feature generated for the ethyl moiety of the inhibitor was removed and a hydrophobic feature was added for the methyl-group of the dihydropteridine core. The pharmacophore model was screened against the Princeton Biomolecular Research, Inc. compound collection (multiconformational format) using the iscreen module implemented in LigandScout 3.1, using default settings.Table 1*In vitro* activity of BDP inhibitors against asexual stage *P. falciparum* Dd2 parasites.Table 1CompoundStructurecLog PIC~50~*Pf*Dd2 (μM)CompoundStructurecLog PIC~50~*Pf*Dd2 (μM)**Chloroquine**![](fx2.gif)4.630.11 (±0.04)**OSSL_258894**[b](#tbl1fnb){ref-type="table-fn"}![](fx3.gif)2.2933.87 (±4.52)**Bromosporine**[a](#tbl1fna){ref-type="table-fn"}![](fx4.gif)1.6726.33 (±7.13)**OSSL_258896**[b](#tbl1fnb){ref-type="table-fn"}![](fx5.gif)3.1633.98 (±21.38)**CPI-203**[a](#tbl1fna){ref-type="table-fn"}![](fx6.gif)3.2881.43 (±13.68)**OSSL_258897**[b](#tbl1fnb){ref-type="table-fn"}![](fx7.gif)3.3735.00 (±0.00)**PFI-4**[a](#tbl1fna){ref-type="table-fn"}![](fx8.gif)2.3526.43 (±3.82)**OSSL_258891**[b](#tbl1fnb){ref-type="table-fn"}![](fx9.gif)2.9940.78 (±28.87)**SGC-CBP30**[a](#tbl1fna){ref-type="table-fn"}![](fx10.gif)5.0910.03 (±0.32)**OSSL_258895**[b](#tbl1fnb){ref-type="table-fn"}![](fx11.gif)2.7547.43 (±8.06)**OSSK_842646**[b](#tbl1fnb){ref-type="table-fn"}![](fx12.gif)4.8311.28 (±2.00)**OSSL_258907**[b](#tbl1fnb){ref-type="table-fn"}![](fx13.gif)2.4371.77 (±20.41)**OSSK_764253**[b](#tbl1fnb){ref-type="table-fn"}![](fx14.gif)3.0732.45 (±15.98)**OSSL_258903**[b](#tbl1fnb){ref-type="table-fn"}![](fx15.gif)4.77\>100**OSSK_764205**[b](#tbl1fnb){ref-type="table-fn"}![](fx16.gif)3.6520.23 (±1.60)**OSSL_258893**[b](#tbl1fnb){ref-type="table-fn"}![](fx17.gif)3.32\>100**OSSK_995759**[b](#tbl1fnb){ref-type="table-fn"}![](fx18.gif)2.7743.24 (±12.43)**OSSL_158302**[b](#tbl1fnb){ref-type="table-fn"}![](fx19.gif)4.7814.70 (±0.00)**OSSL_308235**[b](#tbl1fnb){ref-type="table-fn"}![](fx20.gif)1.7353.83 (±17.10)**OSSK_711135**[b](#tbl1fnb){ref-type="table-fn"}![](fx21.gif)3.20\>100**OSSK_764265**[b](#tbl1fnb){ref-type="table-fn"}![](fx22.gif)1.6457.30 (±19.34)**OSSK_711274**[b](#tbl1fnb){ref-type="table-fn"}![](fx23.gif)4.6336.93 (±20.19)**OSSK_764219**[b](#tbl1fnb){ref-type="table-fn"}![](fx24.gif)1.3572.40 (±3.35)**OSSK_711212**[b](#tbl1fnb){ref-type="table-fn"}![](fx25.gif)2.3587.35 (±1.67)**OSSK_764195**[b](#tbl1fnb){ref-type="table-fn"}![](fx26.gif)2.7972.88 (±8.79)**OSSK_711203**[b](#tbl1fnb){ref-type="table-fn"}![](fx27.gif)4.33\>100**OSSK_764277**[b](#tbl1fnb){ref-type="table-fn"}![](fx28.gif)1.8681.25 (±12.64)**OSSL_094251**[b](#tbl1fnb){ref-type="table-fn"}![](fx29.gif)4.5923.25 (±6.15)**OSSK_842567**[b](#tbl1fnb){ref-type="table-fn"}![](fx30.gif)4.21\>100**OSSK_442833**[b](#tbl1fnb){ref-type="table-fn"}![](fx31.gif)3.4648.06 (±6.79)**OSSK_711132**[b](#tbl1fnb){ref-type="table-fn"}![](fx32.gif)2.29\>100**OSSL_094246**[b](#tbl1fnb){ref-type="table-fn"}![](fx33.gif)2.90\>100**OSSK_447894**[b](#tbl1fnb){ref-type="table-fn"}![](fx34.gif)1.91\>100**OSSK_287503**[b](#tbl1fnb){ref-type="table-fn"}![](fx35.gif)3.12\>100**OSSL_326023**[b](#tbl1fnb){ref-type="table-fn"}![](fx36.gif)2.79\>100**OSSK_695521**[b](#tbl1fnb){ref-type="table-fn"}![](fx37.gif)3.6159.60 (±26.44)**OSSL_258906**[b](#tbl1fnb){ref-type="table-fn"}![](fx38.gif)3.5411.80 (±3.06)**OSSL_094264**[b](#tbl1fnb){ref-type="table-fn"}![](fx39.gif)1.57\>100**OSSL_258905**[b](#tbl1fnb){ref-type="table-fn"}![](fx40.gif)5.2428.82 (±4.58)**OSSK_446201**[b](#tbl1fnb){ref-type="table-fn"}![](fx41.gif)3.9197.20 (±0.00)**OSSL_258904**[b](#tbl1fnb){ref-type="table-fn"}![](fx42.gif)2.9026.03 (±2.24)**OSSK_310407**[b](#tbl1fnb){ref-type="table-fn"}![](fx43.gif)4.40\>100**OSSL_258898**[b](#tbl1fnb){ref-type="table-fn"}![](fx44.gif)3.5628.17 (±4.79)[^2][^3]

2.2. Docking studies {#sec2.2}
--------------------

Pharmacophore hits identified by virtual screening were prepared for docking using the LigPrep tool as implemented in Schrödinger\'s software ([@bib2]), where all possible tautomeric forms as well as stereoisomers were generated and energy minimized using the OPLS force field. The *Pf*GCN5-bromodomain (PDB ID 4QNS) and *Pf*BDP1 (PDB ID 3FKM) crystal structures were retrieved from the PDB. The protein structures were superposed and subsequently prepared with Schrödinger\'s Protein Preparation Wizard: Hydrogen atoms were added and the hydrogen bond network was subsequently optimized. The protonation states at pH 7.0 were predicted using the PROPKA tool within the Schrödinger program. The structures were finally subjected to a restrained energy minimization step using the OPLS2005 force field (RMSD of the atom displacement for terminating the minimization 0.3 Å). The four conserved water molecules lining the bottom of the binding cavity were retained. Receptor grid preparation for the docking procedure was carried out by assigning the conserved asparagine residue as the centroid of the grid box. The ligands were docked into the prepared protein structures using GLIDE (Schrödinger Inc, New York, USA) in the Standard Precision mode.

2.3. *P. falciparum in vitro* culture and growth inhibition assays {#sec2.3}
------------------------------------------------------------------

*P. falciparum* multi-drug resistant Dd2 parasites were cultured in O positive human erythrocytes in RPMI 1640 media (Gibco, USA) supplemented with 10% heat-inactivated pooled human sera and 5 μg/mL gentamicin. Cells were cultured at 37 °C in 5% O~2~ and 5% CO~2~ in N~2~, essentially as previously described ([@bib26]). Growth inhibitory activity of compounds was tested *in vitro* against asexual intraerythrocytic stage parasites over 48 h starting with asynchronous parasites or over 72 h starting with ring-stage parasites, using \[^3^H\]-hypoxanthine-uptake growth inhibition assays, as previously described ([@bib6]). At least three independent assays, each in triplicate wells, were carried out and 50% inhibitory concentrations (IC~50~\'s), determined by log-linear interpolation ([@bib16]). Data are presented as mean IC~50~ (±SD). The antimalarial drug chloroquine served as a positive control.

2.4. Cytotoxicity assays {#sec2.4}
------------------------

Cytotoxicity assays were carried out using human embryonic kidney cells (HEK 293), as previously described ([@bib9]). All assays were carried out in triplicate wells on three separate occasions. Data are presented as mean IC~50~ (±SD), with IC~50~\'s calculated determined by log-linear interpolation ([@bib16]).

3. Results and discussion {#sec3}
=========================

To investigate the anti-plasmodial activity of potential BDP binders/inhibitors (hereafter termed BDPi), a panel of 42 compounds ([Table 1](#tbl1){ref-type="table"}) was tested. Compounds included four known BDPi (bromosporine, CPI-203, PFI-4 and SGC-CBP30; [Table 1](#tbl1){ref-type="table"}) with different mammalian BDP specificities. Bromosporine ([@bib24]) is a pan-BDP inhibitor, while CPI-203 ([@bib14]), PFI-4 ([@bib8]) and SGC-CBP30 ([@bib15]) each have specificity for different mammalian BDPs. A further 38 compounds were selected by virtual screening of the Princeton Biomolecular Research Inc. compound library. These compounds were selected based on *in silico* screening of a pharmacophore-model ([Supplementary Figure S1](#appsec1){ref-type="sec"}) obtained using the crystal structure of PF3D7_0110500 (PDB ID 4PY6) which, at commencement of this study, was the only available structure of a *P. falciparum* bromodomain crystallized in complex with an inhibitor (the PLK1 kinase/BRD4 dual inhibitor BI-2536) ([@bib5]). The 38 compounds identified as potential inhibitors/binders by this virtual screen ([Table 1](#tbl1){ref-type="table"}) span different chemotypes, including some known BDPi scaffolds such as benzimidazolone ([@bib8]; [@bib3]) and triazolophthalazine ([@bib11]).

Docking studies were carried out on all 42 compounds with the available crystal structures of bromodomains of *Pf*GCN5 (PDB ID 4QNS) and PfBDP1 (PDB ID 3FKM). Each compound is predicted to participate in a typical hydrogen bond interaction with the conserved asparagine of *Pf*GCN5 (Asn1436) and a conserved water molecule ([Supplementary Figure S2](#appsec1){ref-type="sec"}; SGC-CBP30, OSSL_258906, OSSL_158302 and OSSK_842646 shown). Additionally, SGC-CBP30 is predicted to have a salt-bridge between the morpholine nitrogen and Glu1389 ([Supplemental Figure S2b](#appsec1){ref-type="sec"}). This salt-bridge is also observed in the previously published crystal structure of the bromodomain of *Pf*GCN5 in complex with triazolophthalazine ([@bib21]) ([Supplemental Figure S2a](#appsec1){ref-type="sec"}). The salt-bridge interaction was not observed for any of the other compounds assessed for anti-plasmodial activity in this study. Docking in the available crystal structure of *Pf*BDP1 (PDB ID 3FKM) was, however, more problematic, since the crystal structure is in apo form, and part of the ZA loop (residues 362--366) is missing. This ZA loop is a highly flexible loop which is known to constitute an important part of the inhibitor-binding pocket of bromodomains ([@bib14]; [@bib22]). Docking studies revealed that the compounds can form hydrogen bond interactions with the conserved Asn413 of *Pf*BDP1, and SGC-CBP30 can also profit from an additional salt bridge with Asp361 ([Supplemental Figure S2f](#appsec1){ref-type="sec"}). While these docking studies provide interesting preliminary predictions regarding interactions with *P. falciparum* BDP(s), future studies are needed to experimentally determine if these specific compounds bind/inhibit *P. falciparum* BDP(s) and, if so, with what specificity. Since the selective CPB/EP300 inhibitor SGC-CBP30 showed the highest antiplasmodial activity among the tested compounds, a BLAST search ([@bib1]) was conducted in order to find the closest homologues of CBP and EP300 bromodomains in *P. falciparum* ([Supplemental Figure S3](#appsec1){ref-type="sec"}). This revealed that *Pf*BDP1 shares the highest homology with CPB and EP300.

*In vitro* 48 h activity assays with asynchronous asexual intraerythrocytic stage *P. falciparum* line Dd2 parasites demonstrated that all 42 BDPi lack potent anti-*Plasmodium* activity (IC~50~ ≥ 10 μM; [Table 1](#tbl1){ref-type="table"}). The three most potent compounds were the CPB/EP300 bromodomain inhibitor SGC-CBP30 (IC~50~ 10.03 (±0.32)), the diethylbenzimidazolone OSSK_842646 (IC~50~ 11.28 (±2.00)) and the triazolophthalazine OSSL_258906 (IC~50~ 11.80 (±3.06)). The activity of these compounds was confirmed in a 72 h assay starting with synchronous ring-stage parasites. The activity of OSSK_842646, OSSL_258906 and the control drug chloroquine was not significantly different between 48 h and 72 h assays (P \> 0.05; [Table 2](#tbl2){ref-type="table"}). While the dimethylisoxazole SGC-CBP30 showed greater activity in the 72 versus 48 h assay ([Table 2](#tbl2){ref-type="table"}; p = 0.006), potency was still low (μM range). Although cytotoxicity studies with SGC-CBP30 suggest low selectivity for the parasite versus HEK 293 cells ([Table 2](#tbl2){ref-type="table"}; ∼7-fold), an IC~50~ value for OSSK_842646, OSSL_258906 against HEK 293 cells was not achieved (IC~50~ \> 50 μM) so selectivity indices could not be accurately determined ([Table 2](#tbl2){ref-type="table"}; \>4-fold).Table 2Comparative anti-plasmodial activity of selected compounds in 48 h versus 72 h growth inhibition assays and cytotoxicity activity against HEK 293 cells.Table 2Compounds*Pf*Dd2 IC~50~ (μM)*p* valueHEK 293 IC~50~ (μM)SI[a](#tbl2fna){ref-type="table-fn"}48 h72 hSGC-CBP3010.03 (±0.32)3.16 (±1.94)0.00622.09 (±2.00)2--7OSSK_84264611.28 (±2.00)6.35 (±2.45)0.073\>50\>4OSSL_25890611.80 (±3.06)5.96 (±1.19)0.051\>50\>4CQ0.11 (±0.04)0.05 (±0.02)0.05218.58 (±1.95)169--372[^4]

The current study describes the anti-plasmodial activity of a panel of compounds known or predicted to bind/inhibit mammalian BDP(s). While data suggest that these compounds have low potency against the *P. falciparum* parasites, they provide a possible starting point for the investigation of rationally designed analogues with improved activity against malaria parasites. In addition, as LC-MS data show that BDPs' are also expressed in sexual stages of *Plasmodium* parasite development ([@bib25]), investigating the activity of these compounds against different *Plasmodium* life cycle stages may be warranted. Further studies on the potential specificity of these compounds for *P. falciparum* BDPs may also validate these inhibitors as chemical tools to study *Plasmodium* epigenetic regulatory processes.

Appendix A. Supplementary data {#appsec1}
==============================
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